. Author manuscript; available in PMC: 2021 Feb 10.

Published in final edited form as: J Med Chem. 2018 Sep 19;62(4):1731–1760. doi: 10.1021/acs.jmedchem.8b01092

Table 1.

Oncogenic TRK Fusions Found across Multiple Tumor Types^a

cancer site	estimated US cases per year	TRKA %	TRKB %	TRKC %
lung adenocarcinoma (NSCLC)	92 138⁴⁶	3.3⁴⁹	0.2⁴⁵
colorectal	135 430¹⁰⁸	1.5^49–52		0.7⁴⁵
intrahepatic cholangiocarcinoma	2 970^109,110	3.6¹¹¹
papillary thyroid cancer	45 496^108,112	12.3⁵³		14.5^54,113
glioblastoma	11 376^108,114	1.25^55,115
head and neck squamous cell carcinoma	63 030¹¹⁶		0.2⁴⁵	0.2¹¹⁷
mammary analogue secretory carcinoma	151^108,118			100¹¹⁹
Ph-like acute lymphoblastic leukemia	1 192^120,121			0.7¹²²
acute myeloid leukemia	15 976^121,123			0.0125^57,124
skin cutaneous melanoma	87 110¹²¹			0.3⁴⁵
secretory breast carcinoma	252^121,125			92¹²⁶
estimated total cases per year		10 917	310	8 325
estimated percent of cases per year		55.8%	1.6%	42.6%

Only positive studies are listed, and thus the actual prevalence may be lower than reported.